HK1035665A1 - Therapeutic compositions (II) - Google Patents
Therapeutic compositions (II)Info
- Publication number
- HK1035665A1 HK1035665A1 HK01106060A HK01106060A HK1035665A1 HK 1035665 A1 HK1035665 A1 HK 1035665A1 HK 01106060 A HK01106060 A HK 01106060A HK 01106060 A HK01106060 A HK 01106060A HK 1035665 A1 HK1035665 A1 HK 1035665A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- patient
- physiologically acceptable
- therapeutic compositions
- acceptable ketosis
- ketosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D323/00—Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Polyesters Or Polycarbonates (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10037198P | 1998-09-15 | 1998-09-15 | |
| PCT/US1999/021015 WO2000015216A1 (en) | 1998-09-15 | 1999-09-15 | Therapeutic compositions (ii) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1035665A1 true HK1035665A1 (en) | 2001-12-07 |
Family
ID=22279402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK01106060A HK1035665A1 (en) | 1998-09-15 | 2001-08-28 | Therapeutic compositions (II) |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20010014696A1 (xx) |
| EP (1) | EP1123094B1 (xx) |
| JP (1) | JP2002524506A (xx) |
| KR (1) | KR100805490B1 (xx) |
| CN (1) | CN1273129C (xx) |
| AT (1) | ATE359069T1 (xx) |
| AU (1) | AU767238B2 (xx) |
| BR (1) | BR9913680A (xx) |
| CA (1) | CA2339941A1 (xx) |
| DE (1) | DE69935799T2 (xx) |
| DK (1) | DK1123094T3 (xx) |
| ES (1) | ES2283133T3 (xx) |
| HK (1) | HK1035665A1 (xx) |
| NZ (1) | NZ509739A (xx) |
| PT (1) | PT1123094E (xx) |
| RU (1) | RU2242227C2 (xx) |
| WO (1) | WO2000015216A1 (xx) |
| ZA (1) | ZA200101260B (xx) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE425750T1 (de) | 2000-05-01 | 2009-04-15 | Accera Inc | Verwendung von triglyceriden mit mittellangen ketten zur behandlung und vorbeugung der alzheimerschen erkrankung |
| US6835750B1 (en) | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
| EP1648952B1 (en) | 2003-06-03 | 2018-03-07 | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives |
| WO2005021013A1 (ja) * | 2003-09-01 | 2005-03-10 | Earthus, Inc. | β−ヒドロキシ短〜中鎖脂肪酸重合体 |
| US7132221B2 (en) * | 2003-09-12 | 2006-11-07 | Headway Technologies, Inc. | Method to print photoresist lines with negative sidewalls |
| GB0410266D0 (en) * | 2004-05-07 | 2004-06-09 | Ketocytonyx Inc | Treatment of apoptosis |
| GB0420856D0 (en) * | 2004-09-20 | 2004-10-20 | Ketocytonyx Inc | Cns modulators |
| WO2006020179A2 (en) | 2004-07-20 | 2006-02-23 | Ketocytonyx Inc. | Oligomeric ketone compounds |
| ES2574557T3 (es) * | 2004-09-21 | 2016-06-20 | Btg International Limited | Miméticos dopaminérgicos |
| GB0427145D0 (en) * | 2004-12-10 | 2005-01-12 | Ketocytonyx Inc | Compositions for use in surgery |
| EP2468273A3 (en) | 2005-06-20 | 2012-07-11 | Accera, Inc. | Method to reduce oxidative damage and improve mitochondrial efficiency |
| JP2009532496A (ja) | 2006-04-03 | 2009-09-10 | アクセラ・インコーポレーテッド | 加齢に伴う記憶障害を治療するためのケト原性化合物の使用 |
| US7807718B2 (en) * | 2006-06-30 | 2010-10-05 | Sami A. Hashim | Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose |
| CN101678043A (zh) | 2007-03-30 | 2010-03-24 | 有限会社爱泽世 | 生酮作用促进剂组合物 |
| RU2459624C2 (ru) * | 2007-04-12 | 2012-08-27 | Риджентс Оф Дзе Юниверсити Оф Миннесота | Защитные композиции от ишемии/реперфузии и способы применения |
| WO2009052182A1 (en) | 2007-10-15 | 2009-04-23 | Jbs United, Inc. | Method for increasing performance of offspring |
| CN101293831B (zh) * | 2007-04-27 | 2013-09-18 | 汕头大学 | 3-羟基脂肪酸及其衍生物在制备钙离子通道调节剂中的用途 |
| US9175345B2 (en) * | 2007-07-31 | 2015-11-03 | Accera, Inc. | Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function |
| CN101969769A (zh) * | 2008-01-04 | 2011-02-09 | 伊希斯创新有限公司 | 用作降低血脂药剂的酮体和酮体酯 |
| CN102105071A (zh) | 2008-07-03 | 2011-06-22 | 艾克塞拉公司 | 用于治疗神经性障碍的乙酰乙酸的单甘油酯及其衍生物 |
| US8105809B2 (en) | 2008-07-03 | 2012-01-31 | Accera, Inc. | Enzymatic synthesis of acetoacetate esters and derivatives |
| US8642654B2 (en) | 2009-04-16 | 2014-02-04 | Isis Innovation Limited | Hydroxybutyrate ester and medical use thereof |
| CA2750510A1 (en) | 2009-01-24 | 2010-07-29 | Phytopharm Plc | Treatment of neurotrophic factor mediated disorders |
| CN102753186B (zh) * | 2010-01-08 | 2016-09-14 | Isis制药公司 | 血管生成素样3表达的调节 |
| GB201002983D0 (en) * | 2010-02-22 | 2010-04-07 | Tdeltas Ltd | Nutritinal composition |
| CA2805693A1 (en) | 2010-07-20 | 2012-01-26 | Phytopharm Plc | Treatment of l-dopa, dopamine agonist and/or dopamine enhancer induced disorders |
| EP2914251B1 (en) | 2012-11-05 | 2019-08-21 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Ketone bodies to protect tissues from damage by ionizing radiation |
| GB201304467D0 (en) | 2013-03-12 | 2013-04-24 | Tdeltas Ltd | Compound for use in protecting skin |
| CN105246870A (zh) | 2013-03-14 | 2016-01-13 | 伊希斯创新有限公司 | (r)-3-羟基丁酸(r)-3-羟基丁酯的制备方法 |
| RU2659386C2 (ru) | 2013-03-19 | 2018-06-29 | Юниверсити Оф Соус Флорида | Композиции и способы, используемые для повышения и поддержания кетоза |
| US10736861B2 (en) | 2016-03-11 | 2020-08-11 | Axcess Global Sciences, Llc | Mixed salt compositions for producing elevated and sustained ketosis |
| US11185518B2 (en) | 2017-12-19 | 2021-11-30 | Axcess Global Sciences, Llc | S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer |
| US10596131B2 (en) | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US11103470B2 (en) | 2017-11-22 | 2021-08-31 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US10245242B1 (en) | 2017-11-22 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US10292952B2 (en) | 2016-03-11 | 2019-05-21 | Axcess Global Sciences, Llc | Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis |
| US11241403B2 (en) | 2016-03-11 | 2022-02-08 | Axcess Global Sciences, Llc | Beta-hydroxybutyrate mixed salt compositions and methods of use |
| US10973792B2 (en) | 2019-02-13 | 2021-04-13 | Axcess Global Sciences, Llc | Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use |
| US10596129B2 (en) | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US10596130B2 (en) | 2017-12-19 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
| US10245243B1 (en) | 2017-12-19 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
| US10973786B2 (en) | 2016-03-11 | 2021-04-13 | Axcess Global Sciences, Llc | R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions |
| US12109182B2 (en) | 2016-04-19 | 2024-10-08 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate and related compounds in humans |
| US11806324B2 (en) | 2018-04-18 | 2023-11-07 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies |
| US11026929B2 (en) | 2016-04-19 | 2021-06-08 | Keto Patent Group, Inc. | Administration of berberine metabolites |
| US10925843B2 (en) | 2018-04-18 | 2021-02-23 | Axcess Global Sciences, Llc | Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate |
| US20180057846A1 (en) | 2016-08-30 | 2018-03-01 | KetoneAid Inc. | Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy |
| US10307398B2 (en) | 2016-09-20 | 2019-06-04 | Regents Of The University Of Minnesota | Resuscitation composition and methods of making and using |
| DK3558280T3 (da) | 2016-12-21 | 2023-08-21 | Univ Kinderspital Beider Basel | Forebyggelse og behandling af migræne |
| EP3558291A1 (en) * | 2016-12-23 | 2019-10-30 | Katholieke Universiteit Leuven | 3-hydroxybutyrate alone or in combination for use in the treatment of critical care treatment |
| US10376528B2 (en) | 2017-03-10 | 2019-08-13 | Tecton Group, Llc | Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor |
| US12171735B2 (en) | 2017-04-19 | 2024-12-24 | Axcess Global Sciences, Llc | Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans |
| US11760963B2 (en) | 2017-08-23 | 2023-09-19 | KetoneAid Inc. | Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol |
| US12090129B2 (en) | 2017-11-22 | 2024-09-17 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US11202769B2 (en) | 2017-11-22 | 2021-12-21 | Axcess Global Sciences, Llc | Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function |
| US11944598B2 (en) | 2017-12-19 | 2024-04-02 | Axcess Global Sciences, Llc | Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer |
| GB2572185A (en) * | 2018-03-21 | 2019-09-25 | Chain Biotechnology Ltd | Pharmaceutical compositions |
| US10980772B2 (en) | 2018-08-27 | 2021-04-20 | Axcess Global Sciences, Llc | Compositions and methods for delivering tetrahydrocannabinol and ketone bodies |
| US11241401B2 (en) | 2020-02-06 | 2022-02-08 | Axcess Global Sciences, Llc | Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions |
| US10512615B1 (en) | 2018-08-27 | 2019-12-24 | Axcess Global Sciences, Llc | Compositions and methods for delivering cannabidiol and ketone bodies |
| US11419836B2 (en) | 2019-02-13 | 2022-08-23 | Axcess Global Sciences, Llc | Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions |
| US11129802B2 (en) | 2018-08-27 | 2021-09-28 | Axcess Global Sciences, Llc | Compositions and methods for delivering cannabidiol and ketone bodies |
| US12167993B2 (en) | 2019-06-21 | 2024-12-17 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| US11969430B1 (en) | 2023-03-10 | 2024-04-30 | Axcess Global Sciences, Llc | Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance |
| US11950616B2 (en) | 2019-06-21 | 2024-04-09 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| US11033553B2 (en) | 2019-06-21 | 2021-06-15 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| IT201900022854A1 (it) * | 2019-12-03 | 2021-06-03 | Dr Schaer S P A | Formulazione alimentare e prodotto alimentare da forno per la gestione della dieta chetogenica |
| US12186297B2 (en) | 2020-08-26 | 2025-01-07 | Axcess Global Sciences, Llc | Compositions and methods for increasing lean-to-fat mass ratio |
| MX2023014990A (es) | 2021-07-17 | 2024-02-14 | Ketoswiss Ag | Combinacion de un cuerpo cetonico o compuesto cetogenico con un analgesico o antioxidante. |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0522422A3 (en) | 1991-07-01 | 1993-03-17 | Mitsubishi Kasei Corporation | Process for producing a biodegradable polymer |
| JP2885261B2 (ja) * | 1993-05-17 | 1999-04-19 | 三菱瓦斯化学株式会社 | ３−ヒドロキシ酪酸のオリゴマー及びその塩からなる輸液製剤 |
| JP4598203B2 (ja) * | 1995-12-01 | 2010-12-15 | ビーティージー・インターナショナル・リミテッド | 脳機能改善剤 |
| DK1017379T3 (en) * | 1997-03-17 | 2015-02-16 | Btg Int Ltd | Therapeutic compositions comprising ketone compounds and precursors thereof |
| US6323237B1 (en) * | 1997-03-17 | 2001-11-27 | Btg International Limited | Therapeutic compositions |
| JP2002500027A (ja) | 1998-01-07 | 2002-01-08 | メタボリックス，インコーポレイテッド | 動物栄養組成物 |
| EP1098655B1 (en) * | 1998-07-22 | 2004-11-24 | Metabolix, Inc. | Nutritional and therapeutic uses of 3-hydroxyalkanoate oligomers |
-
1999
- 1999-09-15 DK DK99946906T patent/DK1123094T3/da active
- 1999-09-15 JP JP2000569800A patent/JP2002524506A/ja active Pending
- 1999-09-15 KR KR1020017003343A patent/KR100805490B1/ko not_active IP Right Cessation
- 1999-09-15 RU RU2001110097/15A patent/RU2242227C2/ru not_active IP Right Cessation
- 1999-09-15 ES ES99946906T patent/ES2283133T3/es not_active Expired - Lifetime
- 1999-09-15 AU AU59212/99A patent/AU767238B2/en not_active Ceased
- 1999-09-15 CN CNB998108375A patent/CN1273129C/zh not_active Expired - Fee Related
- 1999-09-15 CA CA002339941A patent/CA2339941A1/en not_active Abandoned
- 1999-09-15 NZ NZ509739A patent/NZ509739A/en not_active IP Right Cessation
- 1999-09-15 DE DE69935799T patent/DE69935799T2/de not_active Expired - Lifetime
- 1999-09-15 PT PT99946906T patent/PT1123094E/pt unknown
- 1999-09-15 EP EP99946906A patent/EP1123094B1/en not_active Expired - Lifetime
- 1999-09-15 BR BR9913680-5A patent/BR9913680A/pt not_active Application Discontinuation
- 1999-09-15 AT AT99946906T patent/ATE359069T1/de active
- 1999-09-15 WO PCT/US1999/021015 patent/WO2000015216A1/en active IP Right Grant
-
2001
- 2001-02-14 ZA ZA200101260A patent/ZA200101260B/en unknown
- 2001-03-06 US US09/799,124 patent/US20010014696A1/en not_active Abandoned
- 2001-08-28 HK HK01106060A patent/HK1035665A1/xx not_active IP Right Cessation
-
2003
- 2003-12-15 US US10/734,586 patent/US7351736B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1123094B1 (en) | 2007-04-11 |
| US20040171671A1 (en) | 2004-09-02 |
| CN1273129C (zh) | 2006-09-06 |
| EP1123094A1 (en) | 2001-08-16 |
| ATE359069T1 (de) | 2007-05-15 |
| AU5921299A (en) | 2000-04-03 |
| DK1123094T3 (da) | 2007-08-20 |
| ZA200101260B (en) | 2001-08-16 |
| AU767238B2 (en) | 2003-11-06 |
| PT1123094E (pt) | 2007-06-28 |
| US20010014696A1 (en) | 2001-08-16 |
| ES2283133T3 (es) | 2007-10-16 |
| WO2000015216A1 (en) | 2000-03-23 |
| JP2002524506A (ja) | 2002-08-06 |
| KR20010079830A (ko) | 2001-08-22 |
| BR9913680A (pt) | 2001-06-05 |
| DE69935799D1 (de) | 2007-05-24 |
| RU2242227C2 (ru) | 2004-12-20 |
| CN1316902A (zh) | 2001-10-10 |
| US7351736B2 (en) | 2008-04-01 |
| NZ509739A (en) | 2003-10-31 |
| CA2339941A1 (en) | 2000-03-23 |
| KR100805490B1 (ko) | 2008-02-20 |
| DE69935799T2 (de) | 2007-12-27 |
| EP1123094A4 (en) | 2001-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1035665A1 (en) | Therapeutic compositions (II) | |
| BE2018C038I2 (xx) | ||
| IL133585A0 (en) | Soluble prodrugs of paclitaxel | |
| MY130157A (en) | Method of use for inhibiting bone loss and lowering serum cholesterol | |
| GB8712073D0 (en) | Medicament | |
| WO2001036510A3 (en) | Use of poly(diallylamine) polymers | |
| RU94045155A (ru) | Способы ингибирования болезни альцгеймера | |
| RU2001110097A (ru) | Терапевтические композиции (ii) | |
| IL99699A0 (en) | Method of treating or preventing type 1 diabetes by oral administration of insulin | |
| EP0777484A4 (en) | INTRAVENOUS ALENDRONATE FORMULATIONS | |
| IL124977A0 (en) | Oral administration of effective amounts of forms of hyaluronic acid | |
| SE8704248D0 (sv) | Medical use | |
| EP0315591A3 (en) | Physiologically active substances, a process for the preparation thereof and pharmaceutical compositions containing them | |
| SE8500996D0 (sv) | Method of treatment | |
| HU9303000D0 (en) | Aryl-morpholine-derivatives and pharmaceutical compositions containing it and process for production thereof | |
| LV11882A (lv) | Aminotetralina atvasinajumi sirds un asinsvadu slimibu arstesana | |
| DE3688787D1 (de) | Herstellung eines arzneimittels gegen arthritis und rheumatismus. | |
| HUT73500A (en) | Use of benzydamine for producing pharmaceutical compositions for treatment of pathological conditions caused by tnf | |
| SU1475668A1 (ru) | Способ лечени функциональных поражений лицевого нерва | |
| UA10301A (uk) | Спосіб лікуваhhя раку шлуhку | |
| SU944583A1 (ru) | Способ реабилитации травматических поражений мышц | |
| UA30912A (uk) | Спосіб терапії хворих на хронічний обструктивний бронхіт | |
| UA15281A (uk) | Спосіб лікуваhhя хроhічhої ішемічhої хвороби серця | |
| UA30184A (uk) | Спосіб рефлексотерапії хворих з віддаленими наслідками черепно-мозкової травми | |
| CA2167044A1 (en) | Oral administration of effective amounts of forms of hyaluronic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20110915 |